Drug Trial Radar · NCT03833700
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Mar 5, 2019
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Eisai Co., Ltd.Eisai
- Sponsor type
- Industry
- First posted
- Feb 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.
Conditions
- Solid Neoplasms
- Colorectal Neoplasms
- Gastrointestinal Tumors
Interventions
E7386Drug
E7386 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose-limiting Toxicities (DLTs)Time frame: Baseline up to Cycle 1 (Cycle length is equal to [=] 28 days)
- Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 30 days after the last dose of study drug or before initiating post anti-cancer treatment (approximately 6 years)
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Eisai Trial Site #4
Fukuoka, Japan
Eisai Trial Site#6
Osaka, Japan
Eisai Trial Site#7
Nagoya, Aichi-ken, Japan
Eisai Trial Site #2
Kashiwa, Chiba, Japan
Eisai Trial Site #5
Sapporo, Hokkaido, Japan
Eisai Trial Site#8
Sendai, Miyagi, Japan
Eisai Trial Site #3
Nagaizumi-cho, Shizuoka, Japan
Eisai Trial Site #1
Chuo Ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.